Trial Profile
Effect of fingolimod as a second line treatment for relapsing-remitting multiple sclerosis in real life clinical practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2015
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 10 Dec 2015 New trial record